Core Viewpoint - Aikang Medical (01789) has announced a share buyback plan of up to HKD 150 million, which is expected to enhance shareholder value and reflects confidence in the company's financial position [1] Group 1: Share Buyback Announcement - The company plans to utilize its internal financial resources for the proposed share buyback [1] - The buyback will be conducted in the open market on the Hong Kong Stock Exchange until the authorization expires [1] - The company intends to cancel all repurchased shares after settlement in accordance with applicable rules and regulations [1] Group 2: Product Development and Approvals - Aikang Medical's subsidiary, Yidian Lingdong, has received NMPA approval for a Class III medical device registration for a joint replacement surgery navigation system [1] - This system represents the first full joint surgery robot, covering hip, knee, and unicompartmental indications, and is capable of performing revision surgeries [1] - The company has deployed nearly 100 joint robot products in the market, creating effective synergy with its existing prosthetic business [1] - Multiple joint robots are expected to be awarded contracts for public announcement in 2026, establishing a closed-loop from medical engineering integration to clinical application [1]